WuXi Bids Farewell To US Listing As It Vows To ‘Revolutionize R&D’
This article was originally published in PharmAsia News
Being a private company affords WuXi to be more focused on chasing its new drug R&D dream, says the contract clinical research-focused group. But many see a relisting of the company before too long, this time on China's A-share market rather than in the US, in a pattern already established by several other Chinese firms.
Register for our free email digests: